CN103068382A - 用于皮肤修复的化合物和方法 - Google Patents

用于皮肤修复的化合物和方法 Download PDF

Info

Publication number
CN103068382A
CN103068382A CN2011800404387A CN201180040438A CN103068382A CN 103068382 A CN103068382 A CN 103068382A CN 2011800404387 A CN2011800404387 A CN 2011800404387A CN 201180040438 A CN201180040438 A CN 201180040438A CN 103068382 A CN103068382 A CN 103068382A
Authority
CN
China
Prior art keywords
compositions
skin
alkyl
treatment
exist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800404387A
Other languages
English (en)
Chinese (zh)
Inventor
G·L·江
R·M·伯克
W·B·艾姆
F·C·拜丁菲尔德
L·A·惠勒
S·M·惠特卡普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN103068382A publication Critical patent/CN103068382A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
CN2011800404387A 2010-07-30 2011-07-29 用于皮肤修复的化合物和方法 Pending CN103068382A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36923210P 2010-07-30 2010-07-30
US61/369,232 2010-07-30
US41911510P 2010-12-02 2010-12-02
US61/419,115 2010-12-02
PCT/US2011/045833 WO2012016109A2 (en) 2010-07-30 2011-07-29 Compounds and methods for skin repair

Publications (1)

Publication Number Publication Date
CN103068382A true CN103068382A (zh) 2013-04-24

Family

ID=44543791

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800404387A Pending CN103068382A (zh) 2010-07-30 2011-07-29 用于皮肤修复的化合物和方法

Country Status (18)

Country Link
US (1) US20120136011A1 (enExample)
EP (1) EP2598140B1 (enExample)
JP (1) JP2013536183A (enExample)
KR (1) KR20130130694A (enExample)
CN (1) CN103068382A (enExample)
AR (1) AR082428A1 (enExample)
AU (1) AU2011282549A1 (enExample)
BR (1) BR112013002319A2 (enExample)
CA (1) CA2806982A1 (enExample)
CL (1) CL2013000308A1 (enExample)
CO (1) CO6680670A2 (enExample)
MX (1) MX2013001227A (enExample)
NZ (1) NZ607306A (enExample)
PH (1) PH12013500205A1 (enExample)
RU (1) RU2013108394A (enExample)
SG (1) SG187653A1 (enExample)
TW (1) TW201210601A (enExample)
WO (1) WO2012016109A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579438A (zh) * 2013-09-27 2016-05-11 阿勒根公司 用于皮肤修复的化合物和方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697458B2 (en) 2009-04-22 2014-04-15 Shat-R-Shield, Inc. Silicone coated light-emitting diode
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8900571B2 (en) * 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) * 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) * 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8697056B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) * 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) * 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) * 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) * 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
JP2016503422A (ja) * 2012-11-16 2016-02-04 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ プロスタグランジンｅｐ４アゴニストの組み合わせを用いた皮膚創傷の治癒および瘢痕の減少
WO2014078434A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
RU2625548C1 (ru) * 2015-04-29 2017-07-14 Жанна Юрьевна Юсова Способ коррекции возрастных изменений кожи лица
RU2663391C1 (ru) * 2018-01-30 2018-08-03 Игорь Николаевич Бондаренко Способ эстетической коррекции мягких тканей лица

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1563846A1 (en) * 2002-10-10 2005-08-17 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
CN101454281A (zh) * 2006-04-04 2009-06-10 阿勒根公司 前列腺素ep4激动剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
WO2000015608A1 (fr) * 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. Derives e de phenyl-prostaglandine a substitution-φ et medicaments les contenant comme ingredient actif
JP4618548B2 (ja) * 1999-11-24 2011-01-26 小野薬品工業株式会社 骨量低下疾患治療剤
CA2454584C (en) * 2001-07-23 2009-09-22 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising ep4 agonist as active ingredient
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
AU2004211936B2 (en) * 2003-02-11 2008-09-11 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
WO2006016695A1 (ja) * 2004-08-10 2006-02-16 Ono Pharmaceutical Co., Ltd. Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤
JP2006321737A (ja) * 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ｅｐ４アゴニストを含有する神経変性疾患の予防、治療および／または進展抑制剤
JP2007023028A (ja) * 2005-06-16 2007-02-01 Ono Pharmaceut Co Ltd 内耳疾患治療剤
US7439372B2 (en) * 2006-05-03 2008-10-21 Allergan, Inc. Therapeutic compounds
NZ577109A (en) * 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
EP2465506A1 (en) * 2006-12-18 2012-06-20 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
EP2147672A4 (en) * 2007-05-08 2011-11-02 Nat University Corp Hamamatsu University School Of Medicine CYTOTOXIC T CELL ACTIVATOR WITH AN EP4 AGONIST
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1563846A1 (en) * 2002-10-10 2005-08-17 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
CN101454281A (zh) * 2006-04-04 2009-06-10 阿勒根公司 前列腺素ep4激动剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YOSHITADA SAKAI，ET AL: "Prostaglandin E2 Regulates the Expression of Basic Fibroblast Growth Factor Messenger RNA in Normal Human Fibroblasts", 《KOBE JOURNAL OF MEDICAL SCIENCES》, vol. 47, 1 February 2001 (2001-02-01), XP002974917 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579438A (zh) * 2013-09-27 2016-05-11 阿勒根公司 用于皮肤修复的化合物和方法
CN105579438B (zh) * 2013-09-27 2019-12-06 阿勒根公司 用于皮肤修复的化合物和方法

Also Published As

Publication number Publication date
SG187653A1 (en) 2013-03-28
RU2013108394A (ru) 2014-09-10
WO2012016109A3 (en) 2012-03-22
EP2598140A2 (en) 2013-06-05
AU2011282549A1 (en) 2013-02-28
TW201210601A (en) 2012-03-16
CL2013000308A1 (es) 2013-04-12
WO2012016109A2 (en) 2012-02-02
NZ607306A (en) 2015-03-27
KR20130130694A (ko) 2013-12-02
AR082428A1 (es) 2012-12-05
CA2806982A1 (en) 2012-02-02
JP2013536183A (ja) 2013-09-19
US20120136011A1 (en) 2012-05-31
EP2598140B1 (en) 2015-01-14
CO6680670A2 (es) 2013-05-31
BR112013002319A2 (pt) 2016-05-24
PH12013500205A1 (en) 2017-08-23
MX2013001227A (es) 2013-04-24

Similar Documents

Publication Publication Date Title
CN103068382A (zh) 用于皮肤修复的化合物和方法
EP2646017B1 (en) Compounds and methods for skin repair
KR102785243B1 (ko) 몬테루카스트 및 홍합 접착 단백질과의 조합물을 포함하는 국소 제형
US20040052750A1 (en) Compositions for prevention and alleviation of skin wrinkles
JP7061802B2 (ja) 抗老化用組成物
EA024483B1 (ru) Местная композиция для лечения гиперкератотической кожи
CN109310655B (zh) 抗衰老组合物
CN116546971A (zh) 组织源性基质因子组合物和其方法
KR101186130B1 (ko) 니코틴산 아데닌 디뉴클레오티드 인산 또는 그의 유도체를 포함하는 약학적 또는 화장료 조성물
KR101623375B1 (ko) 키토산 및 디카르복실산을 포함하는 주사 질환의 치료용 조성물
JPH04500824A (ja) 光老化の作用を回復させるための皮膚の治療方法
US20170143733A1 (en) Compounds and methods for skin repair
JP2014508806A (ja) 熱抽出された網抽出物、その組成物、その調製方法および使用方法
KR100981089B1 (ko) 히스타민을 함유하는 백반증 치료용 약제학적 조성물
KR101769545B1 (ko) 다프닌을 포함하는 상처 치료용 조성물 및 그의 용도
HK1188953A (en) Compounds and methods for skin repair
JP2017088541A (ja) 異常瘢痕形成抑制剤
CN121129869A (zh) 一种用于皮肤修复的组合物及其制备方法和应用
WO2023274817A1 (en) 1-hydroxy-pyridin-2-one derivatives for use in the treatment of scarring
CN104829678B (zh) 积雪草酸盐及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130424